Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease
Background The prognostic factors of morbidity and mortality in patients with lean NAFLD (body mass index < 25.0 kg/m(2)) are unknown. Methods In this retrospective study, 446 Japanese patients with histopathologically-confirmed NAFLD (lean NAFLD, n = 170) were followed for liver events, cardiova...
Gespeichert in:
Veröffentlicht in: | BMC gastroenterology 2020-11, Vol.20 (1), p.368-368, Article 368 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background The prognostic factors of morbidity and mortality in patients with lean NAFLD (body mass index < 25.0 kg/m(2)) are unknown. Methods In this retrospective study, 446 Japanese patients with histopathologically-confirmed NAFLD (lean NAFLD, n = 170) were followed for liver events, cardiovascular events, type 2 diabetes mellitus, and non-liver malignancies. The median observation period was 4.6 years. We also investigated the predictors of severe fibrosis (stage 3-4) and mortality in lean NAFLD patients. Results Glycolipid metabolic markers, liver function tests, NAFLD fibrosis score (NFS), and histological scoring were significantly lower in lean NAFLD patients than in non-lean NAFLD. The incidence of liver cancer was higher while that of T2DM was lower in lean NAFLD. Kaplan-Meier analysis showed no significant difference in overall survival between the lean and non-lean NAFLD. Multivariate analysis of data of lean NAFLD identified NFS >= - 1.455 as significant independent predictor of severe fibrosis, while history of liver cancer and NFS >= - 1.455 were predictors of overall survival. Conclusions Although patients with lean NAFLD have better histopathological and biochemical profile compared to patients with non-lean NAFLD, the prognosis is not different between the two groups. Lean NAFLD patients with NFS >= - 1.455 or history of liver cancer should be monitored carefully during follow-up. |
---|---|
ISSN: | 1471-230X 1471-230X |
DOI: | 10.1186/s12876-020-01509-3 |